Pharmacological therapies for pediatric and neonatal ALI/ARDS: An evidence-based review

Current Drug Targets

Volumn 13, Issue 7, 2012, Pages 906-916

  de Luca, Daniele ^a   Piastra, Marco ^a   Tosi, Federica ^a   Pulitanò, Silvia ^a   Mancino, Aldo ^a   Genovese, Orazio ^a   Pietrini, Domenico ^a   Conti, Giorgio ^a  

^a UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Children

Indexed keywords

A 001; ACETYLCYSTEINE; ALMITRINE DIMESILATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLARA CELL PROTEIN; CLARA CELL SECRETORY PROTEIN; CORTICOSTEROID; ETANERCEPT; ILOPROST; KETOCONAZOLE; MUSCLE RELAXANT AGENT; NITRIC OXIDE; PENTOXIFYLLINE; PHOSPHOLIPID; PROSTACYCLIN; SILDENAFIL; STEROID; SURFACTANT; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; VARESPLADIB;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANALGESIA; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; HUMAN; INFANT RESPIRATORY DISTRESS SYNDROME; INTENSIVE CARE; LUNG; LUNG LAVAGE; MEDICINE; MUSCLE RELAXATION; NEBULIZER; NONHUMAN; RESPIRATORY DISTRESS SYNDROME; REVIEW; SEDATION;

EID: 84861671013     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012800675687     Document Type: Review

References (157)

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-49.
2. Dahlem P, van Aalderen WM, Bos AP. Pediatric acute lung injury. Paediatr Respir Rev 2007; 8: 348-62.
3. Erickson S, Schibler A, Numa A, et al. Acute lung injury in pediatric intensive care in Australia and New Zealand: A prospective, multicenter, observational study. Pediatr Crit Care Med 2007; 8: 317-23.
4. Randolph AG. Management of acute lung injury and acute respiratory distress syndrome in children. Crit Care Med 2009; 37: 2448-54.
5. De Luca D, Cogo P, Zecca E, et al. Intrapulmonary drug administration in neonatal and paediatric critical care: a comprehensive review. Eur Respir J 2011; 37: 678-89.
6. Scottish Intercollegiate Guidelines Network. SIGN50: a guideline developer's handbook. www.sign.ac.uk/guidelines/fulltext/50. Date last accessed: February 13, 2010. Date last updated: January 2008.
7. Sweet DG, Carnielli V, Greisen G, et al. European association of perinatal medicine. european consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2010 update. Neonatology 2010; 97: 402-17.
8. Engle WA. American academy of pediatrics committee on fetus and newborn. surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008; 121: 419-32.
9. Günther A, Ruppert C, Schmidt R, et al. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res 2001; 2: 353-64.
10. Hallman M, Spragg R, Harrell JH, et al. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982; 70: 673-83.
11. Pison U, Seeger W, Buchhorn R, et al. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 1989; 140: 1033-9.
12. Gregory TJ, Longmore WJ, Moxley MA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88: 1976-81.
13. Günther A, Siebert C, Schmidt R, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996; 153: 176-84.
14. Schmidt R, Meier U, Yabut-Perez M, et al. Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. Am J Respir Crit Care Med 2001; 163: 95-100.
15. Greene KE, Wright JR, Steinberg KP, et al. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999; 160: 1843-50.
16. Hermon MH, Golej J, Burda G, et al. Surfactant therapy in infants and children: three years experience in a pediatric intensive care unit. Shock 2002; 17: 247-51.
17. Herting E, Moller O, Schiffmann JH, et al. Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome. Acta Paediatr 2002; 91: 1174-8.
18. Onarheim H, Vik V. Porcine surfactant (Curosurf) for acute respiratory failure after near-drowning in 12 years old. Acta Anaesthesiol Scand 2004; 48: 778-81.
19. Marx M, Golej J, Furst G, et al. Exogenous surfactant and high frequency oscillatory ventilation in a child with severe adult respiratory distress after near-drowning. Wien Klin Wochenschr 1995; 107: 146-8.
20. Moller JC, Schaible TF, Reiss I, et al. Treatment of severe nonneonatal ARDS in children with surfactant and nitric oxide in a 'pre-ECMO'-situation. Int J Artif Organs 1995; 18: 598-602.
21. Suzuki H, Ohta T, Iwata K, et al. Surfactant therapy for respiratory failure due to near-drowning. Eur J Pediatr 1996; 155: 383-4.
22. Tegtmeyer FK, Moller J, Zabel P. Inhibition of granulocyte activation by surfactant in a 2-yr-old female with meningococcusinduced ARDS. Eur Respir J 2002; 19: 776-9.
23. Woerndle S, Bartmann P. The effect of three surfactant preparations on in vitro lymphocyte function. J Perinat Med 1994; 22: 119-28.
24. Schrama AJ, Elferink JG, Hack CE, et al. Pulmonary secretory phospholipase A2 in infants with respiratory distress syndrome stimulates in vitro neutrophil migration. Neonatology 2010; 97: 1-9.
25. Granata F, Frattini A, Loffredo S, et al. Signaling events involved in cytokine and chemokine production induced by secretory phospholipase A2 in human lung macrophages. Eur J Immunol 2006; 36: 1938-50.
26. Berger A, Vial D, Havet N, et al. Phosphatidylglycerol mediates the inhibition by pulmonary surfactant of secretory phospholipase A2 expression in alveolar macrophages. Am J Respir Crit Care Med 1999; 159: 613-28.
27. Hidi R, Vial D, Hvet N, et al. Semi-natural surfactant inhibits the expression of secretory phospholipase A2 by guinea pig alveolar macrophages. Biochem Pharmacol 1997; 54: 1055-8.
28. el Hanache A, Gourrier E, Karoubi P, et al. Modification of Creactive protein after instillation of natural exogenous surfactants. Arch Pediatr. 1997; 4: 27-31. [Article in French]
29. Duffett M, Choong K, Ng V, et al. Surfactant therapy for acute respiratory failure in children: a systematic review and metaanalysis. Critical Care 2007; 11: R66.
30. Ventre K, Haroon M, Davison C. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database Syst Rev 2006; 3: CD005150.
31. Taeusch HW. Treatment of acute (adult) respiratory distress syndrome. The holy grail of surfactant therapy. Biol Neonate 2000; 77: 2-8.
32. Wirbelauer J, Speer CP. The role of surfactant treatment in preterm infants and term newborns with acute respiratory distress syndrome. J Perinatol 2009; 29(Suppl 2): S18-22.
33. El Shahed AI, Dargaville PA, Ohlsson A, et al. Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane Database Syst Rev 2007; CD002054.
34. Dargaville PA, Mills JF, Headley BM, et al. Therapeutic lung lavage in the piglet model of meconium aspiration syndrome. Am J Respir Crit Care Med 2003; 168: 456-63.
35. Wiswell TE, Knight GR, Finer NN, et al. A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 2002; 109: 1081-7.
36. Salvia-Roigés MD, Carbonell-Estrany X, Figueras-Aloy J, et al. Efficacy of three treatment schedules in severe meconium aspiration syndrome. Acta Paediatr 2004; 93: 60-5.
37. Gadzinowski J, Kowalska K, Vidyasagar D. Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO. J Perinatol 2008; 28 Suppl 3: S56-66.
38. Dargaville PA, Copnell B, Mills JF, et al. on behalf of the lessMAS Trial Study Group. Randomized Controlled Trial of Lung Lavage with Dilute Surfactant for Meconium Aspiration Syndrome. J Pediatr 2011; 158: 383-9.
39. Balaraman V, Meister J, Ku TL, et al. Lavage administration of dilute surfactants after acute lung injury in neonatal piglets. Am J Respir Crit Care Med 1998; 158: 12-7.
40. Balaraman V, Sood SL, Finn KC, et al. Physiologic response and lung distribution of lavage versus bolus Exosurf in piglets with acute lung injury. Am J Respir Crit Care Med 1996; 153: 1838-43.
41. Meister JC, Balaraman V, Ku T, et al. Lavage administration of dilute recombinant surfactant in acute lung injury in piglets. Pediatr Res 2000; 47: 240-5.
42. Rooney SA. The surfactant system and lung phospholipid biochemistry. Am Rev Respir Dis 1985; 131: 439-60.
43. Wright JR, Clements JA. Metabolism and turnover of lung surfactant. Am Rev Respir Dis 1987; 136: 426-44.
44. Van Golde LM, Batenburg JJ, Robertson B. The pulmonary surfactant system: Biochemical aspects and functional significance. Physiol Rev 1988; 68: 374-455.
45. Wiswell TE, Smith RM, Katz LB, et al. Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 160: 1188-95.
46. Marraro GA, Luchetti M, Spada C, et al. Selective medicated (normal saline and exogenous surfactant) bronchoalveolar lavage in severe aspiration syndrome in children. Pediatr Crit Care Med 2007; 8: 476-81.
47. Konduri GG. New approaches for persistent pulmonary hypertension of newborn. Clin Perinatol 2004; 31: 591-611.
48. Macrae DJ, Field D, Mercier JC, et al. Inhaled nitric oxide therapy in neonates and children: reaching a European consensus. Intensive Care Med 2004; 30: 372-80.
49. Barr FE, Macrae D. Inhaled nitric oxide and related therapies. Pediatr Crit Care Med 2010; 11(2 Suppl): S30-6.
50. Ichinose F, Ullrich R, Sapirstein A, et al. Cytosolic phospholipase A(2) in hypoxic pulmonary vasoconstriction. J Clin Invest 2002; 109: 1493-500.
51. Hassoun PM, Mouthon L, Barberà JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54(1 Suppl): S10-9.
52. Nakano Y, Tasaka S, Saito F, et al. Endothelin-1 level in epithelial lining fluid of patients with acute respiratory distress syndrome. Respirology 2007; 12: 740-3.
53. Romand JA, Donald FA, Suter PM. Cardiopulmonary interactions in acute lung injury: Clinical and prognostic importance of pulmonary hypertension. New Horiz 1994; 2: 457-62.
54. Greene JH, Klinger JR. The efficacy of inhaled nitric oxide in the treatment of acute respiratory distress syndrome. An evidencebased medicine approach. Crit Care Clin 1998; 14: 387-409.
55. Brett SJ, Evans TW. Measurement of endogenous nitric oxide in the lungs of patients with the acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157 (3 Pt 1): 993-7.
56. Abman SH, Griebel JL, Parker DK, et al. Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure. J Pediatr 1994; 124: 881-8.
57. Okamoto K, Hamaguchi M, Kukita I, et al. Efficacy of inhaled nitric oxide in children with ARDS. Chest 1998; 114: 827-33.
58. Sheridan RL, Zapol WM, Ritz RH, et al. Low-dose inhaled nitric oxide in acutely burned children with profound respiratory failure. Surgery 1999; 126: 856-62.
59. Fong Tang S, Sherwood MC, Miller OI. Randomised trial of three doses of inhaled nitric oxide in acute respiratory distress syndrome. Arch Dis Child 1998; 79: 415-8.
60. Gerlach H, Keh D, Semmerow A, et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am J Respir Crit Care Med 2003; 167: 1008-15.
61. Afshari A, Brok J, Møller AM, et al. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults (Review). Cochrane Database Syst Rev 2010; 7: CD002787.
62. Afshari A, Brok J, Møller AM, et al. inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis. Anesth Analg 2011; [Epub ahead of print].
63. Fioretto R, de Moraes MA, Bonatto RC, et al. Acute and sustained effects of early administration of inhaled nitric oxide to children with acute respiratory distress syndrome. Pediatr Crit Care Med 2004; 5: 469-74.
64. Hammer J. Acute lung injury: pathophysiology, assessment and current therapy. Paediatr Resp Rev 2000; 2: 10-21.
65. Desai AR, Deep A. ventilatory strategies and adjunctive therapy in ards. Indian J Pediatr 2006; 73: 661-8.
66. Howard LSGE, Morrell NW. New therapeutic agents for pulmonary vascular diseases. Pediatr Resp Rev 2005; 6: 285-91.
67. Schermuly RT, Inholte C, Ghofrani HA, et al. Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respir Res. 2005 Jul 20; 6: 76.
68. Dani C, Pavoni V, Corsini I, et al. Inhaled nitric oxide combined with prostacyclin and adrenomedullin in acute respiratory failure with pulmonary hypertension in piglets. Pediatr Pulmonol. 2007; 42: 1048-56.
69. Coleman DM, Kelly HW, McWilliams BC. Therapeutic aerosol delivery during mechanical ventilation. Ann Pharmacother 1996; 30: 644-55.
70. Pappert D, Busch T, Gerlach H, et al. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology 1995; 82: 1507-11.
71. Dahlem P, van Aalderen WM, de Neef M, et al. Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Crit Care Med 2004; 32: 1055-60.
72. Afshari A, Brok J, Møller AM, et al. Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev 2010; 8: CD007733.
73. Putensen C, Hörmann C, Kleinsasser A, et al. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157: 1743-7.
74. Baquero H, Soliz A, Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006; 117: 1077-83.
75. Moloney ED, Evans TW. Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome. Eur Respir J 2003; 21: 720-7.
76. Cornet AD, Hofstra JJ, Swart EL, et al. Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDS. Intensive Care Med 2010; 36: 758-64.
77. Fok TF. Adjunctive pharmacotherapy in neonates with respiratory failure. Semin Fetal Neonat Med 2009; 14: 49-55.
78. Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest 1997; 112: 164-72.
79. Pacht ER, Timerman AP, Lykens MG, et al. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest 1991; 100: 1397-403.
80. Bunnel E, Pacht ER. Oxidized glutathione is increased in the alveolar fluid of patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1993; 148: 1174-8.
81. Bernard GR. N-acetylcysteine in experimental and clinical acute lung injury. Am J Med 1991; 91(suppl 3C): 54S-9S.
82. Adhikari N, Burns KE, Meade MO. Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev 2004; 4: CD004477.
83. Adhikari N, Burns KE, Meade MO. Pharmacologic treatments for acute respiratory distress syndrome and acute lung injury: systematic review and meta-analysis. Treat Respir Med 2004; 3: 307-28.
84. Desai MH, Mlcak R, Richardson J, et al. Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/ N-acetylcystine [correction of acetylcystine] therapy. J Burn Care Rehabil 1998; 19: 210-2. Erratum in: J Burn Care Rehabil 1999; 20(1 Pt 1): 49.
85. Lauterbach R, Pawlik D, Kowalczyk D, et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit Care Med 1999; 27: 807-14.
86. ter Horst SAJ, Wagenaar GTM, de Boer E, et al. Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. J Appl Physiol 2004; 97: 2014-9.
87. Balibrea-Cantero JL, Arias-Diaz J, Garcia C, et al. Effect of pentoxifylline on the inhibition of surfactant synthesis induced by TNF-alpha in human type II pneumocytes. Am J Respir Crit Care Med 1994; 149: 699-706.
88. Kullmann A, Vaillant P, Muller V, et al. In vitro effects of pentoxifylline on smooth muscle cell migration and blood monocyte production of chemotactic activity for smooth muscle cells: potential therapeutic benefit in the adult respiratory distress syndrome. Am J Respir Cell Mol Biol 1993; 8: 83-8.
89. Touqui L, Wu YZ. Interaction of secreted phospholipase A2 and pulmonary surfactant and its pathophysiological relevance in acute respiratory distress syndrome. Acta Pharmacol Sin 2003; 24: 1292-6.
90. Meduri GU, Annane D, Chrousos GP, et al. Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest 2009; 136: 1631-43.
91. Meduri GU, Tolley EA, Chrousos GP, et al. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory syndrome: Evidence for inadequate endogenous gluco-corticoid secretion and intlammationinduced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002; 165: 983-91.
92. Meduri GU, Tolley EA, Chinn A, et al. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998; 158: 1432-41.
93. O'Leary EC, Evans GF, Zuckerman SH. In vivo dexamethasone effects on neutrophil effector functions in a rat model of acute lung injury. Inflammation 1997; 21: 597-608.
94. Kuwabara K, Furue S, Tomita Y, et al. Effect of methylprednisolone on phospholipase A2 activity and lung surfactant degradation in acute lung injury in rabbits. Eur J Pharmacol 2001; 433: 209-16.
95. Tripathi S, Saili A, Dutta R. Inflammatory markers in meconium induced lung injury in neonates and effect of steroids on their levels: a randomized controlled trial. Indian J Med Microbiol 2007; 25: 103-7.
96. Tripathi S, Saili A. The effect of steroids on the clinical course and outcome of neonates with meconium aspiration syndrome. J Trop Pediatr 2007; 53: 8-12.
97. Basu S, Kumar A, Bhatia BD, et al. Role of steroids on the clinical course and outcome of meconium aspiration syndrome-a randomized controlled trial. J Trop Pediatr 2007; 53: 331-7.
98. Martinot A, Fourier C, Cremer R, et al. Short-course, highdose corticosteroid treatment in six children with late ARDS. Pediatr Pulmonol 1997; 23: 314-6.
99. Goh AY, Sekaran D, Roziah M. Corticosteroid rescue in late paediatric acute respiratory distress syndrome Respirology 1999; 4: 295-7.
100. Lundy CT, Shield JP, Kvittingen EA, et al. Acute respiratory distress syndrome in long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial trifunctional protein deficiencies. J Inherit Metab Dis 2003; 26: 537-41.
101. Meduri GU, Headly AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. JAMA 1998; 280: 159-65.
102. Guglani L, Jain S, Lodha R. Methylprednisolone therapy in a child with unresolving ARDS. Indian Pediatr 2006; 43: 639-42.
103. Peter JV, John P, Graham PL, et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008; 336: 1006-9.
104. Randolph AG. Management of acute lung injury and acute respiratory distress syndrome in children. Crit Care Med 2009; 37: 2448-54.
105. Mantile G, Miele L, Cordella-Miele E, et al. Human Clara Cell 10-kDa Protein Is the Counterpart of Rabbit Uteroglobin. J Biol Chem 1993; 268: 20343-51.
106. Pilon AL. Rationale for the development of recombinant human CC10 as a therapeutic for inflammatory and fibrotic disease. Ann N Y Acad Sci 2000; 923: 280-99.
107. Kropsk JA, Fremont RD, Calfee CS, et al. Clara Cell Protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest 2009; 135: 1440-7.
108. Jorens PG, Sibille Y, Goulding NJ, et al. Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury. Eur Respir J 1995; 8: 1647-53.
109. De Luca D, Minucci A, Cogo P, et al. Secretory phospholipase A pathway during pediatric acute respiratory distress syndrome: a preliminary study. Pediatr Crit Care Med 2011; 12: e20-4.
110. Wang SZ, Rosenberger CL, Bao YX, et al. Clara cell secretory protein modulates lung inflammatory and immune responses to respiratory syncytial virus infection. J Immunol 2003; 171: 1051-60.
111. Han WK, Sapirstein S, A, Hung CC, et al. Cross talk between cytosolic phospholipase A2 (cPLA2) and secretory phospholipase A2 (sPLA2) in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells. J Biol Chem 2003; 278: 24153-63.
112. Liu T, Zaman W, Kaphalia BS, et al. RSV-induced prostaglandin E2 production occurs via cPLA2 activation: role in viral replication. Virology 2005; 343: 12-24.
113. American Academy of Pediatrics. Subcommittee on Diagnosis and Management of Bronchiolitis Diagnosis and Management of Bronchiolitis. Pediatrics 2006; 118: 1774-93.
114. Lesur O, Langevin S, Berthiaume Y, et al. critical care research group of the québec respiratory health network. outcome value of clara cell protein in serum of patients with acute respiratory distress syndrome. Intensive Care Med 2006; 32: 1167-74.
115. De Luca D, Minucci A, Tripodi D, et al. Role of distinct phospholipases A2 and their modulators in meconium aspiration syndrome in human neonates. Intensive Care Med 2011; in press.
116. Levine CR, Gewolb IH, Allen K, et al. The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res 2005l; 58: 15-21.
117. Schevitz RW, Bach NJ, Carlson DG, et al. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nature Struct Biol 1995; 2: 458-65.
118. Snyder DW, Bach NJ, Dillard RD, et al. Pharmacology of LY315920/S-5920,1 [3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate, a Potent and Selective Secretory Phospholipase A2 Inhibitor: A New Class of Anti-Inflammatory Drugs, SPI. J Pharmacol Exp Ther 1999; 288: 1117-24.
119. Smart BP, Oslund RC, Walsh LA, et al. The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding. J Med Chem 2006; 49: 2858-60.
120. Abraham E, Naum C, Bandi V, et al. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14 kDa group IIA phospholipase A2 in patients with suspected sepsis and organ failure. Crit Care Med 2003; 31: 718-28.
121. Zeiher GB, Steingrub J, Laterre PF, et al., for the EZZI study. LY315920Na/S-5920, a selective group IIA phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit Care Med 2005; 33: 1741-8.
122. Rosenson RS, Elliott M, Stasiv Y, et al., for the PLASMA II Investigators. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. Eur Heart J 2011; [Epub ahead of print].
123. Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2009; 31: 463-93.
124. Rosenson RS, Hislop C, McConnell D, et al. PLASMA Investigators Effects of 1-h-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): A phase II double-blind, randomised, placebo-controlled trial. Lancet 2009; 373: 649-58.
125. Rosenson RS, Hislop C, Elliott M, et al. Effects of Varespladib Methyl onBiomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients. J Am Coll Cardiol 2010; 56; 1079-88.
126. Martin CM, Guyatt G, Montori VM. The sirens are singing: the perils of trusting trials stopped early and subgroup analyses. Crit Care Med 2005; 33: 1870-1.
127. Furue S, Kuwabara K, Mikawa K, et al. Crucial role for group IIphospholipase A2 in oleic acid-induced acute lung injury in rabbits. Am J Resp Crit Care Med 1999; 160: 1292-302.
128. Furue S, Mikawa K, Nishina K, et al. Therapeutic time window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection. Crit Care Med 2001; 29: 719-27.
129. Nakos G, Kitsiouli E, Hatzidaki E, et al. Phospholipase A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med 2005; 33: 772-9.
130. De Luca D, Carnielli VP, Trias J, et al., on behalf of the Study Group on Secretory Phospholipase A2 in neonatal critical care. New antiinflammatory therapy for neonatal acute lung injury: varespladib (A-001) inhibits ex vivo secretory phospholipase. 3rd congress of European Academy of Pediatrics. Young Investigator Award Session. Copenhagen 2010. Ped Research 2010; (suppl 1): 14 (n.22).
131. De Luca D, Minucci A, Trias J, et al., on behalf of the Study group on Secretory Phospholipase in Pediatrics. Varespladib inhibits secretory phospholipase A2 in bronchoalveolar lavage of different types of neonatal lung injury. J Clin Pharmacol 2012; 52(5): 729-37.
132. Warren RB, Griffiths CE. The future of biological therapies. Semin Cutan Med Surg. 2010; 29: 63-6.
133. Raghavendran K, Pryhuber GS, Chess PR, et al. Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome. Curr Med Chem 2008; 15: 1911-24.
134. Wallis RS, Schluger NW. Pulmonary infectious complications of tumor necrosis factor blockade. Infect Dis Clin North Am 2010; 24: 681-92.
135. Zimmer C, Beiderlinden M, Peters J. Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis. Clin Rheumatol 2006; 25: 430-2.
136. Randolph AG, Wypij D, Venkataraman ST, et al. Effect of mechanical ventilator weaning protocols on respiratory outcomes in infants and children: A randomized controlled trial. JAMA 2002; 288: 2561-8.
137. Wolf A, Weir P, Segar P, et al. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet 2001; 357: 606-7.
138. Schweickert WD, Hall J. ICU-acquired weakness. Chest 2007; 131: 1541-9.
139. Bordet F, Contamin B, Berthier JC, et al. Tetraparesis in an infant after prolonged administration of pancuronium. Ann Fr Anesth Reanim 1995; 14: 426-8 [article in French].
140. Papazian L, Forel JM, Gacouin A, et al. ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363: 1107-16.
141. Idell S. Anticoagulants for acute respiratory distress syndrome: can they work? Am J Respir Crit Care Med 2001; 164: 517-20.
142. Cesana BM, Antonelli P, Chiumello D, et al. Positive end-expiratory pressure, prone positioning, and activated protein C: a critical review of meta-analyses. Minerva Anestesiol. 2010; 76: 929-36.
143. Lee JW. Beta2 adrenergic agonists in acute lung injury? The heart of the matter. Crit Care 2009; 13: 1011.
144. Presneill JJ, Harris T, Stewart AG, et al. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002; 166: 138-43.
145. Sinuff T, Cook DJ, Peterson JC, et al. Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis J Crit Care 1999; 14: 1-6.
146. Slotman GJ, Burchard KW, D'Arezzo A, et al. Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J Trauma 1988; 28: 648-54.
147. Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1993; 21: 1635-42.
148. Network ARDS. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network. JAMA 2000; 283: 1995-2002.
149. Papazian L, Roch A, Bregeon F, et al. Inhaled nitric oxide and vasoconstrictors in acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 160: 473-9.
150. Jolliet P, Bulpa P, Ritz M, et al. Additive beneficial effects of the prone position, nitric oxide, and almitrine bismesylate on gas exchange and oxygen transport in acute respiratory distress syndrome. Crit Care Med 1997; 25: 786-94.
151. Gillart T, Bazin JE, Cosserant B, et al. Combined nitric oxide inhalation, prone positioning and almitrine infusion improve oxygenation in severe ARDS. Can J Anesth 1998; 45: 402-9.
152. B'chir A, Mebazaa A, Losser MR, et al. Intravenous almitrine bismesylate reversibly induces lactic acidosis and hepatic dysfunction in patients with acute lung injury. Anesthesiology 1998; 89: 823-30.
153. Wysocki M, Roupie E, Langeron O, et al. Additive effect on gas exchange of inhaled nitric oxide and intravenous almitrine bismesylate in the adult respiratory distress syndrome. Intensive Care Med 1994; 20: 254-9.
154. Lu Q, Mourgeon E, Law-Koune J, et al. Dose-response curves of inhaled nitric oxide with and without intravenous almitrine in nitric oxide-responding patients with acute respiratory distress syndrome. Anesthesiology 1995; 83: 929-43.
155. Roch A, Papazian L, Bregeon F, et al. High or low doses of almitrine bismesylate in ARDS patients responding to inhaled NO and receiving norepinephrine? Intensive Care Med 2001; 27: 1737-43.
156. Michard F, Wolff MA, Herman B, et al. Right ventricular response to high-dose almitrine infusion in patients with severe hypoxemia related to acute respiratory distress syndrome. Crit Care Med 2001; 29: 32-6.
157. Doering EB, Hanson CW 3rd, Reily DJ, et al. Improvement in oxygenation by phenylephrine and nitric oxide in patients with adult respiratory distress syndrome. Anesthesiology 1997; 87: 18-25.